Xlife Sciences AG Updates on VERAXA Biotech's NASDAQ Listing

Xlife Sciences AG has provided an update on the NASDAQ listing process of its portfolio company, VERAXA Biotech AG. Following a lengthy 43-day U.S. government shutdown, the U.S. Securities and Exchange Commission (SEC) has finally responded to VERAXA's initial filing, enabling VERAXA to amend its Form F-4 as of November 28, 2025. This marks a significant step in VERAXA's planned business combination with Voyager Acquisition Corp., a U.S.-listed SPAC.

VERAXA's extraordinary general meeting is expected in December 2025 to consider shareholder approvals necessary for the merger. Pending standard regulatory processes, Xlife Sciences anticipates the NASDAQ listing to conclude in the first quarter of 2026. Oliver R. Baumann, CEO of Xlife Sciences AG, expressed confidence in both the transaction timeline and VERAXA's aim to become a leader in oncology therapeutics.